Cerlapirdine

Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which was under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia.[1] In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events,[2] but no further development has occurred since 2011.[3]

Cerlapirdine
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
ChEMBL
Chemical and physical data
FormulaC22H23N3O3S
Molar mass409.501 g/mol g·mol−1
3D model (JSmol)

It exerts its effects by acting as a selective 5-HT6 receptor antagonist.[1]

See also

References
  1. Codony X, Vela JM, Ramírez MJ (February 2011). "5-HT(6) receptor and cognition". Current Opinion in Pharmacology. 11 (1): 94–100. doi:10.1016/j.coph.2011.01.004. hdl:10171/18451. PMID 21330210.
  2. Franco Borsini (2011). International review of neurobiology: Pharmacology of 5-HT6 receptors. Part 2. Academic Press. p. 5. ISBN 978-0-12-385902-0. Retrieved 25 October 2011.
  3. Drug Profile: Cerlapirdine
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.